Discounted Cash Flow (DCF) Analysis Unlevered

Rallybio Corporation (RLYB)

$4.7

+0.15 (+3.30%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 4.7 | undervalue

Operating Data

Year
A/P
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ---------
Revenue (%)
EBITDA ---------
EBITDA (%)
EBIT ---------
EBIT (%)
Depreciation ---------
Depreciation (%)

Balance Sheet Data

Year
A/P
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Total Cash ---------
Total Cash (%)
Account Receivables ---------
Account Receivables (%)
Inventories ---------
Inventories (%)
Accounts Payable ---------
Accounts Payable (%)
Capital Expenditure ---------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 4.7
Beta 0.000
Diluted Shares Outstanding 31.82
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 3.528
Total Debt 0.56
Total Equity 149.56
Total Capital 150.12
Debt Weighting 0.37
Equity Weighting 99.63
Wacc

Build Up Free Cash

Year
A/P
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ---------
EBITDA ---------
EBIT ---------
Tax Rate -0.59%-6.04%-3.31%0.00%-2.48%-2.48%-2.48%-2.48%-2.48%
EBIAT ---------
Depreciation ---------
Accounts Receivable ---------
Inventories ---------
Accounts Payable ---------
Capital Expenditure -0.19-0.14--0.05-----
UFCF ---------
WACC
PV UFCF ---------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 3.53
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -56.40
Equity Value -
Shares Outstanding 31.82
Equity Value Per Share -